Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MariMed Inc. (MRMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, quarterly updates, and annual reports filed with the U.S. Securities and Exchange Commission. As a multi-state cannabis operator and cannabis consumer packaged goods company, MariMed uses these filings to report on its financial condition, operating performance, and material events.
Investors can review documents such as Form 8-K current reports, where MariMed furnishes press releases announcing quarterly results and other significant developments. These filings typically reference revenue, gross margin, net income or loss, and non-GAAP measures like Adjusted EBITDA and non-GAAP gross margin, along with management’s discussion of how these metrics are used to evaluate the business.
Through its periodic reports, MariMed also describes risks, uncertainties, and factors that could affect future performance, including changes in customer spending, regulatory approvals, and integration of acquired operations. Forward-looking statements in these filings are accompanied by cautionary language directing readers to additional risk discussions in the company’s reports.
On Stock Titan, each new MariMed filing is captured from the SEC’s EDGAR system and paired with AI-powered summaries that highlight key points, such as updates to financial results, explanations of non-GAAP metrics, and descriptions of material events. Users can quickly scan these summaries, then open the full filing for deeper review. This page also helps track items like insider and executive-related disclosures when they are reported on SEC forms, giving a structured view of MariMed’s regulatory reporting history.
MariMed Inc. Chief Operating Officer Timothy Shaw exercised restricted stock units into common stock. On April 2, 2026, 9,982 RSUs converted to 9,982 shares of common stock on a one-for-one basis, increasing his direct holdings.
Of these shares, 3,459 were withheld by MariMed to cover tax withholding obligations, leaving Shaw with 9,357,700 shares of common stock held directly. Separately, 2,000,000 shares are held indirectly by the Shaw Family Trust for the benefit of his children, and he disclaims beneficial ownership of those securities. The RSU grant continues, with 9,981 RSUs scheduled to vest on October 2, 2026, and 9,982 RSUs on April 2, 2027.
MariMed Inc. President and CEO Jon R. Levine reported routine equity compensation activity. On April 2, 2026 he exercised 11,518 Restricted Stock Units, receiving the same number of common shares at no cash cost as the RSUs convert one-for-one into stock.
To cover tax obligations tied to this vesting, 3,992 common shares were withheld by MariMed at a price of $0.0691 per share, leaving Levine with a net increase of 7,526 shares. After these transactions, he directly holds 21,158,974 common shares.
The filing also notes 6,684,640 common shares held by the Jon Levine Family Trust for the benefit of his spouse and children; Levine disclaims beneficial ownership of these trust shares. The RSUs were granted on April 2, 2024, with the remaining units scheduled to vest in equal installments on October 2, 2026 and April 2, 2027.
MariMed Inc. Chief Commercial Officer Ryan Crandall exercised vested equity awards and settled taxes in shares. On March 28, 2026, he converted 6,047 Restricted Stock Units (RSUs) into the same number of common shares at an exercise price of $0.00 per share.
Of these shares, 2,096 common shares were withheld by MariMed at a value of $0.0758 per share to satisfy tax withholding obligations, with the remainder added to his holdings. Following these transactions, Crandall directly held 879,634 shares of common stock. The RSUs originated from a March 28, 2024 grant, with an additional 6,046 RSUs scheduled to vest on September 28, 2026 and 6,047 RSUs on March 28, 2027.
MariMed Inc. is a U.S. multi-state cannabis operator focused on vertically integrated medical and adult-use markets. The company develops, owns, and operates cultivation, processing, and Thrive-branded retail facilities, and sells proprietary brands such as Nature’s Heritage, Betty’s Eddies, Bubby’s Baked, Vibations, and InHouse.
Operations span Massachusetts, Delaware, Illinois, Maryland, and Ohio, with additional licensing and management relationships in Pennsylvania and New York. As of June 30, 2025, non-affiliate equity was valued at $22.6 million, and at March 10, 2026, there were 397,882,764 common shares outstanding.
The company highlights its “Expand the Brand” growth plan, regulatory and tax risks from federal illegality and Section 280E, and notes IRS tax liens filed in 2025 it is contesting. It reports a 2023 cybersecurity incident causing a $0.7 million loss and 923 employees as of December 31, 2025.
MariMed Inc. reported fourth quarter and full year 2025 results showing modest revenue growth but lower margins and profitability. Full year revenue was $159.8 million, up slightly from $157.7 million in 2024, while GAAP net loss widened to $14.5 million from $12.4 million. Non-GAAP Adjusted EBITDA was $16.9 million versus $19.3 million, marking a sixth consecutive year of positive Adjusted EBITDA but at a lower margin. In Q4 2025, revenue rose to $41.7 million from $38.9 million, with GAAP gross margin declining to 25%. Management highlighted 11% wholesale revenue growth, distribution reaching 85% of dispensaries in core markets, and leading edible rankings for Betty’s Eddies. The company also restructured $14.725 million of Series B preferred stock, extending the weighted average maturity by 4.6 years to reduce near-term refinancing risk and support liquidity.
MARIMED INC. Chief Operating Officer Timothy Shaw exercised 21,667 restricted stock units into an equal number of common shares on March 7, 2026, at a stated price of $0.00 per share. These RSUs were originally granted on March 7, 2023 and are now fully vested with no remaining units under that grant.
To cover tax withholding from this vesting, 7,508 common shares were withheld at $0.084 per share, reducing his directly held common stock to 9,351,177 shares. Separately, 2,000,000 common shares are held indirectly by the Shaw Family Trust for the benefit of his children; his spouse serves as trustee, and he disclaims beneficial ownership of those trust shares.
MariMed Inc. President and CEO Jon R. Levine reported equity compensation activity involving restricted stock units and common shares. He exercised 23,333 restricted stock units into 23,333 shares of common stock at a stated price of $0.0000 per share, reflecting a derivative exercise/conversion.
To cover tax withholding obligations from this RSU vesting, 8,085 common shares were withheld at $0.0840 per share, leaving him with 21,151,448 shares of common stock held directly after these transactions. An additional 6,684,640 common shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children, and he disclaims beneficial ownership of those trust-held securities.
MariMed Inc. Chief Commercial Officer Ryan Crandall reported equity compensation activity involving restricted stock units (RSUs) that convert to common shares on a one-for-one basis. On the reported date, 12,500 RSUs were exercised into 12,500 shares of common stock at no cash exercise price.
To satisfy tax withholding obligations tied to this RSU vesting, 4,332 common shares were withheld by the company. After these transactions, Crandall’s direct ownership in MariMed common stock stood at 875,683 shares.
MARIMED INC. Chief Operating Officer Timothy Shaw reported equity compensation activity involving restricted stock units (RSUs) and common shares. On March 1, 2026, 65,000 RSUs were exercised, converting on a one-for-one basis into 65,000 shares of common stock at a stated price of $0.0000 per share.
To cover tax withholding obligations tied to this RSU vesting, 22,523 shares of common stock were withheld by the company at $0.0848 per share, reducing the net shares retained. After these transactions, Shaw directly held 9,337,018 shares of MARIMED common stock.
The filing also notes 2,000,000 shares of common stock held indirectly by the Shaw Family Trust. Shaw’s spouse is the trustee, and the trust benefits their children; Shaw disclaims beneficial ownership of these trust-held securities. The RSUs involved were granted on September 1, 2023, with remaining units scheduled to vest on September 1, 2026 under an award agreement.
MariMed Inc. entered into a restructuring agreement with Navy Capital that cancels its prior Series B preferred stock obligation tied to a potential cash payment of approximately $14.2 million. In its place, MariMed issued two new promissory notes totaling $8,000,000 and new Series B preferred shares.
The notes comprise $2,000,000 due on March 1, 2028 at 8% interest and $6,000,000 due on March 1, 2031 at 10%, with a possible rate reduction if the first note is repaid within six months. MariMed also issued 26,900,000 non-voting New Series B Convertible Preferred shares with a liquidation preference of $6,725,000 that rank senior to common stock for dividends and liquidation and are convertible into common stock under specified price and VWAP conditions.